Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.56 |
| ▸ | YES1 | P07947 | 5/20 | 0.56 |
| ▸ | FGR | P09769 | 5/20 | 0.56 |
| ▸ | FYN | P06241 | 5/20 | 0.52 |
| ▸ | LYN | P07948 | 3/20 | 0.52 |
| ▸ | ABL1 | P00519 | 5/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | FRK | P42685 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | PRKDC | P78527 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7894961 | 0.84 | PIK3CG (0.48) | SRCYES1FGRABL1PIK3CA | |
| SCHEMBL15613596 | 0.81 | SRC (0.65) | SRCYES1FGRFYNLYN | |
| SCHEMBL22539896 | 0.80 | YES1 (0.42) | SRCYES1FGRFYNLYN | |
| SCHEMBL16127376 | 0.78 | SRC (0.53) | SRCYES1FGRFYNLYN | |
| SCHEMBL30405328 | 0.76 | PIK3CD (0.52) | SRCABL1RETPIK3CAPIK3CG | |
| SCHEMBL20553545 | 0.76 | PIK3CD (0.52) | SRCABL1RETPIK3CAPIK3CG | |
| SCHEMBL3613904 | 0.74 | SRC (0.67) | SRCABL1RETPIK3CAPIK3CG | |
| SCHEMBL2965908 | 0.73 | IGF1R (0.71) | — | |
| SCHEMBL20132621 | 0.72 | SRC (1.00) | SRCYES1FGRFYNLYN | |
| SCHEMBL25678139 | 0.70 | MTOR (0.49) | SRCYES1FGRABL1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| EP-2976086-B1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-8450480-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012151562-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010051043-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051042-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | SRC 68/4885YES1 279/4885FGR 951/4885 |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, MTOR, AURKA | SRC 1374/4885YES1 351/4885FGR 3815/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | SRC 68/4885YES1 279/4885FGR 951/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | SRC 825/4885YES1 959/4885FGR 2704/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | SRC 1515/4885YES1 1954/4885FGR 2619/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | SRC 248/4885YES1 358/4885FGR 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.